Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

New needle-free injector system for administering human growth hormone launched by Teva

Antares Pharma, Inc. (NYSE Amex: AIS) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) has launched its new Tjet™ needle-free injector system for the administration of human growth hormone (hGH). The Tjet™ device will be available exclusively in combination with the Teva hGH product Tev-Tropin® [somatropin (rDNA) for injection].

26 Aug 2009

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has raised an aggregate $5 million of gross proceeds through a private placement of units ("August 2009 Private Placement") and through the exercise of warrants (the "Warrant Exchange") originally issued in connection with its May/June 2008 private placement.

25 Aug 2009

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it has exceeded 90% enrollment reaching 85 patients for its pivotal Phase III Metastatic Melanoma Trial.

25 Aug 2009

FDA issues final approval for manufacturing and marketing Ranbaxy's Glycopyrrolate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Glycopyrrolate Tablets USP, 1 mg and 2 mg.

25 Aug 2009

Milestone Scientific receives Notice of Allowance to use disposable hand piece for fluid administration

Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for Milestone's U.S. patent application directed to the use of its disposable hand piece for fluid administration.

25 Aug 2009

NIAID funds Nanotherapeutic for developing an inhaled version of the injectable antiviral drug

Nanotherapeutics, Inc., today announced that it has been awarded a $30.9 Million, 5-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exposure prophylaxis and treatment of the Category A bioterrorism agent smallpox (Variola major).

25 Aug 2009

Phase I/II trial of Amphinex uses photochemical internalisation approach

PCI Biotech Holding ASA, the Norwegian drug delivery company focusing on effective delivery of cancer therapeutics, today announced that the first patient has received treatment in the Phase I/II trial with the lead candidate Amphinex(R), which uses a new approach called photochemical internalisation.

25 Aug 2009

FDA issues warning letter to Cambrex concerning its Italian API manufacturing facility

Cambrex Corporation (the "Company") announced that it has received a warning letter from the U.S. Food and Drug Administration ("FDA") relating to an inspection of the Company's generic active pharmaceutical ingredient ("API") manufacturing facility located in Milan, Italy in March 2009. The observations noted in the warning letter are primarily related to the collection and maintenance of certain laboratory data.

25 Aug 2009

Impax Laboratories to be listed in NASDAQ

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Larry Hsu, Ph.D., President and Chief Executive Officer of Impax Laboratories, Inc., will preside over the NASDAQ Opening Bell on Monday, August 24, 2009 at the NASDAQ MarketSite® in New York City’s Times Square.

24 Aug 2009

Emisphere Technologies announces sale of common stock shares resulting in gross proceeds of $4 million

Emisphere Technologies, Inc. today announced the completion of its previously announced sale of 5,714,286 shares of its common stock and warrants to purchase up to 2,685,714 additional shares of common stock in a registered direct offering with two institutional investors, resulting in gross proceeds of $4 million (the “Financing”).

24 Aug 2009

Biovail's patent infringement lawsuit against Cary Pharma may affect IntelGenx revenues

IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma") had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®.

24 Aug 2009

Omnicomm's TrialMaster EDC solution chosen by Impax Pharmaceuticals for study in Parkinson's disease

OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that Impax Pharmaceuticals, the brand division of Impax Laboratories, Inc., Hayward, CA, has selected the TrialMaster EDC solution for conducting a Phase III study in patients with Parkinson's Disease. "While managing a global multi site clinical trial there can be significant challenges in getting trial data when you want it and in the format that you need it," said Suneel Gupta, PhD, Chief Scientific Officer for Impax. "The TrialMaster EDC solution provides us with an intuitive and easy to use export tool that simplifies the process. After considering multiple different EDC solutions, we selected OmniComm Systems based on its customer driven approach and reputation for delivering unparalleled service and support. Additionally, its support of industry standards has enabled us to meet our very tight corporate timelines for this important study."

21 Aug 2009

Emisphere Technologies to sell securities for funding its operations

Emisphere Technologies, Inc. (OTC BB: EMIS) today announced that it has received commitments from two institutional investors to purchase $4 million of securities in a registered direct offering. Emisphere entered into a securities purchase agreement with these investors pursuant to which Emisphere has agreed to sell an aggregate of 5,714,286 shares of its common stock and warrants to purchase up to 2,685,714 additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.47 of a share of common stock, will be sold for a purchase price of $0.70.

20 Aug 2009

3M introduces Littmann electronic stethoscope with Bluetooth

Taking the stethoscope into the 21st century, 3M today announced the introduction of the 3M™ Littmann® Electronic Stethoscope Model 3200, a next-generation auscultation device featuring Bluetooth technology that wirelessly transfers heart, lung and other body sounds to software for further analysis.

19 Aug 2009

Omnia Biologics and Aparna Biosciences sign agreement on lentivirus drug development

Biologics contract manufacturer Omnia Biologics, Inc. (Omnia) (Rockville, MD) and drug development company Aparna Biosciences Corp. (AparnaBio) (Rockville, MD) today announced a deal for Omnia to provide AparnaBio with process development and production services. Omnia will provide lentiviral vector technical services as well as manufacture of research grade through cGMP grade materials.

19 Aug 2009

Light-activated delivery system enhances anti-tumour drug potency

The effects of tumour-targeting drugs in mice are significantly enhanced by PCI Biotech's light-activated delivery system, a new study shows. Researchers say this dual therapy approach could be employed to increase the effect and lower the side effects of anti-cancer drugs in humans.

19 Aug 2009

BioDelivery Sciences International utilizes ICR's services for shareholder communications program

BioDelivery Sciences International, Inc. (BDSI®) (Nasdaq:BDSI) today announced that it has retained ICR, a leading investor relations and strategic advisory firm, to assist in the Company's shareholder communications program. ICR, founded in 1998 by a group of former institutional capital markets professionals, is headquartered in Westport, Connecticut, with offices in Westport, New York, Los Angeles, Boston, Chicago, Minneapolis, Beijing, and Shanghai.

19 Aug 2009

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

The University of Southern California today announced that two faculty members from the USC Viterbi School of Engineering have been recognized by Technology Review magazine as some of the world's top innovators under the age of 35. Andrea Armani, Assistant Professor of Chemical Engineering and Materials Science, and Ellis Meng, Assistant Professor of Biomedical Engineering, will both appear on the prestigious 2009 TR35 list.

19 Aug 2009

Scientists harness carbon nanomaterials for drug delivery, oxygen sensors

Two nanoscale devices recently reported by University of Pittsburgh researchers in two separate journals harness the potential of carbon nanomaterials to enhance technologies for drug or imaging agent delivery and energy storage systems, in one case, and, in the other, bolster the sensitivity of oxygen sensors essential in confined settings, from mines to spacecrafts.

17 Aug 2009

Alpharx completes lyophilization process for Zysolin

AlphaRx Inc. has announced that it has completed the lyophilization process for Zysolin(TM), allowing the company to proceed to clinical batch material manufacturing for human trials. This process has been solely developed by AlphaRx's scientists and the resulting formulations have been successfully tested in animal studies conducted by the U.S. Army under a Material Transfer Agreement.

17 Aug 2009

Drug Delivery News and Research

Further Reading

New needle-free injector system for administering human growth hormone launched by Teva

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

FDA issues final approval for manufacturing and marketing Ranbaxy's Glycopyrrolate tablets

Milestone Scientific receives Notice of Allowance to use disposable hand piece for fluid administration

NIAID funds Nanotherapeutic for developing an inhaled version of the injectable antiviral drug

Phase I/II trial of Amphinex uses photochemical internalisation approach

FDA issues warning letter to Cambrex concerning its Italian API manufacturing facility

Impax Laboratories to be listed in NASDAQ

Emisphere Technologies announces sale of common stock shares resulting in gross proceeds of $4 million

Biovail's patent infringement lawsuit against Cary Pharma may affect IntelGenx revenues

Omnicomm's TrialMaster EDC solution chosen by Impax Pharmaceuticals for study in Parkinson's disease

Emisphere Technologies to sell securities for funding its operations

3M introduces Littmann electronic stethoscope with Bluetooth

Omnia Biologics and Aparna Biosciences sign agreement on lentivirus drug development

Light-activated delivery system enhances anti-tumour drug potency

BioDelivery Sciences International utilizes ICR's services for shareholder communications program

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

Scientists harness carbon nanomaterials for drug delivery, oxygen sensors

Alpharx completes lyophilization process for Zysolin

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News